Kelly, W. K., Srinivas, S., Maly, J., Kilari, D., Hussain, A., Saraiya, B., Siddiqui, B. A., Monk, P., Chatta, G. S., Narayan, V., Rana, D., Thanigaimani, P., Fang, F., Skokos, D., Kirshner, J., Seebach, F. A., Lowy, I., Ingham, M., Sandigursky, S., Miller, E. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps295